BPM31510 + Vitamin K1 for Glioblastoma
Trial Summary
Will I have to stop taking my current medications?
You may need to stop taking certain medications to participate in this trial. Specifically, you cannot take therapeutic doses of anticoagulants (blood thinners), digitalis alkaloids (heart medications), antiangiogenic drugs (cancer treatments), or theophylline (a medication for breathing problems).
What data supports the effectiveness of the drug BPM31510 + Vitamin K1 for treating glioblastoma?
Research shows that BPM31510, which delivers high levels of ubidecarenone (a form of CoQ10), can selectively target and kill glioblastoma cells by exploiting their vulnerability to oxidative stress. In animal models, this approach led to a significant increase in long-term survival rates, suggesting its potential as an effective treatment for this aggressive brain cancer.12345
Is BPM31510 (ubidecarenone) safe for human use?
Ubidecarenone (CoQ10) has been used safely as a dietary supplement and in complementary therapies for heart failure for over two decades, with no reported genotoxic (DNA-damaging) effects in studies. Additionally, CoQ10 formulations have shown no obvious toxicity in lung cell studies, suggesting it is generally safe for human use.16789
What makes the drug BPM31510 + Vitamin K1 unique for treating glioblastoma?
BPM31510 delivers high levels of ubidecarenone (a form of Coenzyme Q10) directly to cancer cells, exploiting their vulnerability to oxidative stress, which can selectively kill tumor cells without harming normal cells. This approach is novel because it targets the cancer cells' unique metabolic reprogramming, unlike most treatments that do not differentiate between cancerous and non-cancerous cells.1241011
What is the purpose of this trial?
This is a single-arm, non-randomized, open-label Phase 2 therapeutic study that will assess the effects of adding BPM31510 onto a conventional treatment framework of RT and concurrent TMZ chemotherapy for subjects with newly diagnosed glioblastoma.
Eligibility Criteria
This trial is for adults over 18 with newly diagnosed glioblastoma who haven't had prior treatments like radiation or chemotherapy. They should be able to understand the study and consent, have a life expectancy of at least 3 months, and a Karnofsky score of 60 or more. Participants must not be pregnant, avoid pregnancy during the trial, and be two weeks post-surgery.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Dose-confirmation
Establish safety of BPM31510 in combination with RT and TMZ using a 3+3 dose design
Treatment
Participants receive BPM31510 infusion and concurrent RT and TMZ chemotherapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- BPM31510
Find a Clinic Near You
Who Is Running the Clinical Trial?
BPGbio
Lead Sponsor
Berg, LLC
Lead Sponsor
BPGbio
Collaborator